About Alcresta Therapeutics

Daniel Orlando is the Chief Executive Officer of Alcresta Therapeutics.  He joins the team with more than 18 years of executive management and corporate development experience leading organizations through rapid growth in the development, manufacturing and commercialization of therapeutics and biologics.  Prior to joining Alcresta Therapeutics, Daniel was most recently the Chief Operating Officer of Vericel Corporation, an autologous cell therapy company, which purchased the cell therapy and regenerative medicine business unit from Sanofi Genzyme.  During his tenure, he led every function at Vericel, most recently, Sales, Marketing, Manufacturing, Engineering, and Research & Development.   Before joining Vericel, Daniel was one of Takeda North America’s early employee’s and held executive positions in Business Development, Marketing, and Sales as well as similar developmental roles at Abbott Laboratories.  Daniel holds a BA in Economics with Honors from the University of Florida and an MBA from Florida Atlantic University.

Bill Scheinler is Chief Legal and Compliance Officer and Secretary at Alcresta Therapeutics. He brings years of experience as a leader in public and private medical device and pharmaceutical companies, and as a specialist in compliance, contracting, mergers and acquisitions, and licensing. Bill was previously Vice President, Associate General Counsel for Ikaria, Inc., where he helped transform a business that was expected to face generic competition into a durable customer service-focused franchise with growing revenues, resulting in a five-fold increase in enterprise value. Among his responsibility at Ikaria were driving and supporting multiple in-licensing and product acquisition/divestiture transactions, the spin-out of the company’s R&D business to a stand-alone public company, developing effective and compliant business sustainability strategies, resolving complex, high value commercial disputes, and overseeing company contracting, including contracts with customers and key suppliers. Prior to joining Ikaria, Bill was Associate General Counsel at VIASYS Healthcare, Inc., a public healthcare technology company with four business units focused in respiratory care, neurology, medical disposables, surgical products, and orthopedics. At VIASYS, he supported the company’s global expansion strategy, including the acquisition of 11 companies to grow the company’s revenues by four times and enterprise value by more than three times. Before joining VIASYS, Bill was in the business and finance group at Morgan, Lewis & Bockius LLP, with a focus in technology transactions, licensing, outsourcing, supply and distribution arrangements, and mergers and acquisitions. Bill holds a J.D. from Temple University - James E. Beasley School of Law and an M.A. in International Policy Analysis from Middlebury Institute of International Studies at Monterey.

Jason Weiner is the Chief Commercial Officer of Alcresta Therapeutics. He joins the team with more than 17 years of industry and strategy consulting experience in the biopharmaceutical industry.  Prior to Alcresta, Jason was the Vice President of Marketing and Market Access at Vericel Corporation, an autologous cell therapy company, where during his tenure he led all marketing and market access related activities for the cell therapy and regenerative medicine franchise. Included was the expansion and build-out of the commercial team and development of an innovative patient access and distribution program. Jason held developmental Sales roles at Pfizer and Astellas before leading strategy engagements as a consultant at Charles River Associates where he advised on issues related to customer engagement, payer marketing, drug launches, physician research, sales force alignment, market access, and pricing strategy. Jason holds a BA in History from Union College and an MBA from Boston College.

Chris Parrish is the Chief Operations Officer of Alcresta Therapeutics. He joins Alcresta with more than 25 years of biotech and medical device industry experience. Prior to joining Alcresta, Chris was Vice President of Manufacturing at Vericel Corporation, an autologous cell therapy company, where during his tenure he also led quality and worked in research and development. In addition to leading Manufacturing Operations through completion of clinical trials, Chris has also supported product launch and commercial success of cell therapy products. Chris started his career with Pfizer as a scientist in research and development and quality.